Resource utility {#S1}
================

This TRNDi010-C iPSC line presents a patient-specific disease model for studies of NGLY1 deficiency phenotype and pathophysiology and can be used as a cell-based model for drug discovery and therapeutic development to treat NGLY1 patients.

Resource details {#S2}
================

NGLY1 deficiency, also known as NGLY1-related congenital disorder of deglycosylation, is a rare autosomal recessive disorder caused by mutations in the *NGLY1* gene which encodes a specialized enzyme called N-glycanase that removes N-linked glycan from glycosylated proteins within the body. Deficiency of this protein can lead to malfunctions of cellular functions and accumulation of misfolded proteins within cells in specific tissues or organs. The symptoms and severity of this disease can dramatically vary among affected individuals, who may have developmental delays, intellectual disability, movement disorders, seizures, liver disease, and alacrima ([@R3]; [@R4]; [@R2]).

In this study, a human dermal fibroblast was derived from a 16-year-old female patient (GM26612, Coriell Institute) with a homozygous nonsense mutation of p.R401X (c.1201A \> T) in exon 8 of the *NGLY1* gene (3p24.2) ([@R3]; [@R5]). The iPSC line, TRNDi010-C, was reprogramed from the fibroblasts using the non-integrating CytoTune-Sendai viral vector kit (A16517, Thermo Fisher Scientific) containing four pluripotency transcription factors, OCT3/4, KLF4, SOX2, and c-MYC ([@R1]). Individual colonies were picked, expanded and further analyzed at the cellular and genetic level to confirm successful reprogramming ([Table 1](#T1){ref-type="table"}). The TRNDi010-C iPS cells displayed the standard pluripotent stem cell morphology under phase contrast microscopy and expressed pluripotency markers OCT4, NANOG and SOX2 in the nuclei and SSEA4 and TRA-1--60 on the plasma membrane ([Fig. 1A](#F1){ref-type="fig"}). The quantitative analysis by flow cytometry revealed 98.36% and 84.09% expression rate of TRA-1--60 and NANOG, respectively ([Fig. 1B](#F1){ref-type="fig"}). G-banded karyotyping analysis was used to confirm the karyotype, which showed the normal diploid 46, XX, without any detectable abnormalities ([Fig. 1C](#F1){ref-type="fig"}). The genetic mutation, c.1201A \> T (p.R401X), was validated by Sanger sequencing of the PCR product harboring the single nucleotide variant ([Fig. 1D](#F1){ref-type="fig"}), consistent with the description of Coriell Institute. After passage 30, the exogenous reprogramming factors were eliminated from TRNDi010-C iPSCs, despite the remaining low level of SeV ([Fig. 1E](#F1){ref-type="fig"}). To further test the pluripotency of this iPSC line, teratoma formation experiment was performed. As shown in [Fig. 1F](#F1){ref-type="fig"}, the imaging data identified its ability to generate derivative of three germ layers, ectoderm, mesoderm and endoderm *in vivo*. Furthermore, this iPSC was negative for mycoplasma contamination ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). The STR DNA profile of the TRNDi010-C matched with its parental GM26612 fibroblast at all 18 loci (information available with the authors).

Materials and methods {#S3}
=====================

Cell culture and reprogramming {#S4}
------------------------------

Patient skin fibroblasts were obtained from Coriell Cell Repositories (GM26612), and cultured in DMEM supplemented with 10% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin in a humidified incubator with 5% CO~2~ at 37 °C. Patient fibroblasts were reprogrammed into iPSCs using the non-integrating Sendai virus technology ([@R1]). Human iPSCs were cultured in mTeSR™1 (STEMCELL Technologies) on Matrigel (Corning, 354277)-coated plates at 37 °C in humidified air with 5% CO~2~ and 5% O~2~. The cells were passaged with ReLeSR™ (STEMCELL Technologies) at generally 1:10 ratio when they reached around 70% confluency.

Genome analysis {#S5}
---------------

The genome analysis of variants in NGLY1 was conducted through Applied StemCell (Milpitas, California, USA). Briefly, genomic DNA was extracted from iPSC line TRNDi010-C using QuickExtract™ DNA Extraction Solution (Lucigen) followed by PCR amplification using MyTaq™ Red Mix (Bioline, Taunton, MA). Amplifications were carried out on T00 Thermal Cycler from Bio-Rad (\#1861096) using the following program: 95 °C, 2 min; 35 cycles of \[95 °C, 15 s; 60 °C, 15 s; 72 °C, elongation duration varies by amplicon size\], 72 °C 5 min; 4 °C, indefinite. Genotyping of the homozygous for the p.R401X variant (c.1201 A \> T) in exon 8 of the *NGLY1* gene was performed using Sanger sequencing analysis. The specific primers for gene amplification and sequencing are listed in [Table 2](#T2){ref-type="table"}.

Immunocytochemistry {#S6}
-------------------

iPSC colonies, cultured in the 96-well plate, were washed with Dulbecco's phosphate-buffered saline (DPBS) without Ca^2+^ and Mg^2+^ and fixed in 4% paraformaldehyde for 15 min at room temperature. Fixed cells were washed with DPBS twice, and permeabilized with 0.1% Triton X-100 in DPBS for 15 min. After 1 h of blocking, the cells were incubated with primary antibodies, diluted in the blocking buffer, for overnight at 4 °C. Cells were washed twice with DPBS and a corresponding secondary antibody conjugated with Alexa Fluor 488 or Alex Fluor 647 was added to the cells and incubated for 1 h at room temperature (Antibodies used are listed in [Table 2](#T2){ref-type="table"}). Cells were then stained with Hoechst 33342 for 15 min and imaged using an INCell Analyzer 2500 imaging system (GE Healthcare) with Cy5, FITC and DAPI filter sets.

Flow cytometry analysis {#S7}
-----------------------

The iPSCs were dissociated by TrypLE Express enzyme (Thermo Fisher Scientific). After washing once with DPBS, cells were fixed with 4% paraformaldehyde for 10 min and were permeabilized with 0.2% Tween-20 in DPBS for another 10 min at room temperature, followed by staining with fluorophore-conjugated antibodies ([Table 2](#T2){ref-type="table"}) for 1 h at 4 °C. The cells were then analyzed on a BD AccuriC6 FlowCytometry system (BD Biosciences).

G-banded karyotyping {#S8}
--------------------

The G-banded karyotyping analysis was performed by the WiCell Research Institute (Madison, WI) using the iPS cells at passage 6. Twenty randomly selected metaphase cells were selected for the standard cytogenetic analysis.

Short tandem repeat (STR) analysis {#S9}
----------------------------------

The STR analysis of patient fibroblasts and iPSCs was performed by the Johns Hopkins University Genetic Resources Core Facility using the Promega PowerPlex 18D Kit. The ABI Prism® 3730xl Genetic Analyzer was used to electrophorese the PCR products and GeneMapper® v 4.0 software (Applied Biosystems) was used to analyze the data.

Mycoplasma detection {#S10}
--------------------

The Lonza MycoAlert kit was used to assess the mycoplasma according to the instructions from the company. B/A ratio \> 1.2 indicates the positive sample; 0.9--1.2 indicates the ambiguous result; \< 0.9 indicates the negative sample.

Sendai virus detection {#S11}
----------------------

Using the RNeasy Plus Mini Kit (Qiagen), the total RNA was extracted. The cDNA was reverse-transcribed from 1 μg RNA by SuperScript™ III First-Strand Synthesis SuperMix (Thermo Fisher Scientific). The Platinum II Hot-Start PCR Master Mix (Thermo Fisher Scientific) was used to amplify the target sequence with a PCR program: 94 °C, 2 min; 30 cycles of 94 °C, 15 s, 60 °C, 15 s, and 68 °C, 15 s on Mastercycler pro S (Eppendorf) with the specific primers ([Table 2](#T2){ref-type="table"}). The human fibroblasts (GM05659, Coriell Institute) transfected with Sendai virus for 4 days was used as the positive control.

Teratoma formation assay {#S12}
------------------------

Patient iPSCs were dissociated with 0.5 mM EDTA in PBS and were resuspended approximately 1 × 10^7^ cells in 400 μL culture medium supplied with 25 mM HEPES (pH 7.4) and stored on ice. Then, 50% volume (200 μL) of cold Matrigel (Corning, 354277) was added and mixed with the cells. The mixture was injected subcutaneously into NSG mice (JAX No. 005557) at 150 μL per injection site. Visible tumors were removed 6--8 weeks post-injection and were immediately fixed in 10% Neutral Buffered Formalin. The fixed tumors were embedded in paraffin and stained with hematoxylin and eosin.
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======================
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###### 

Characterization and validation.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification                        Test                                   Result                                                                        Data
  ------------------------------------- -------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------
  Morphology                            Photography                            Normal                                                                        [Fig. 1 Panel A](#F1){ref-type="fig"}

  Phenotype                             Immunocytochemistry                    SOX2, OCT4, NANOG, SSEA-4, TRA-1--60                                          [Fig. 1 Panel A](#F1){ref-type="fig"}

                                        Flow cytometry                         TRA-1--60 (98.36%); NANOG (84.09%)                                            [Fig. 1 Panel B](#F1){ref-type="fig"}

  Genotype                              Karyotype (G-banding) and resolution   46XX\                                                                         [Fig. 1 Panel C](#F1){ref-type="fig"}
                                                                               Resolution: 350--400                                                          

  Identity                              Microsatellite PCR (mPCR) OR           Not performed                                                                 N/A

                                        STR analysis                           18 sites tested, all sites matched                                            Available with the authors

  Mutation analysis (IF APPLICABLE)     Sequencing                             Homozygous mutation\                                                          [Fig. 1 Panel D](#F1){ref-type="fig"}
                                                                               *NGLY1*, p.R401X                                                              

                                        Southern Blot OR WGS                   N/A                                                                           N/A

  Microbiology and virology             Mycoplasma                             Mycoplasma testing by luminescence. Negative                                  [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}

  Differentiation potential             Teratoma formation                     Teratoma with three germ layers formation, ectoderm, mesoderm and endoderm.   [Fig. 1 Panel F](#F1){ref-type="fig"}

  Donor screening (OPTIONAL)            HIV 1 + 2 Hepatitis B, Hepatitis C     N/A                                                                           N/A

  Genotype additional info (OPTIONAL)   Blood group genotyping                 N/A                                                                           N/A

                                        HLA tissue typing                      N/A                                                                           N/A
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagents details.

  -------------------------------------------------------- ------------------------------------------ ---------- --------------------------------------------------------
  Antibodies used for immunocytochemistry/flow-cytometry                                                         
                                                                                                                 
                                                           Antibody                                   Dilution   Company Cat \# and RRID
                                                                                                                 
  Pluripotency Markers                                     Mouse anti-SOX2                            1:50       R & D systems, Cat\# MAB2018, RRID: AB_358009
  Pluripotency Markers                                     Rabbit anti-NANOG                          1:400      Cell signaling, Cat\# 4903, RRID: AB_10559205
  Pluripotency Markers                                     Rabbit anti-OCT4                           1:400      Thermo Fisher, Cat\# A13998, RRID: AB_2534182
  Pluripotency Markers                                     Mouse anti-SSEA4                           1:1000     Cell signaling, Cat\# 4755, RRID: AB_1264259
  Pluripotency Markers                                     Mouse anti- TRA-1--60                      1:1000     Cell signaling, Cat\# 4746, RRID: AB_2119059
  Secondary Antibodies                                     Donkey anti-Mouse IgG (Alexa Fluor 488)    1:400      Thermo Fischer, Cat\# A21202, RRID: AB_141607
  Secondary Antibodies                                     Donkey anti-Rabbit IgG (Alexa Fluor 594)   1:400      Thermo Fischer, Cat\# A21207, RRID: AB_141637
  Flow Cytometry Antibodies                                Anti-Tra-1--60-DyLight 488                 1:50       Thermo Fischer, Cat\# MA1--023-D488X, RRID: AB_2536700
  Flow Cytometry Antibodies                                Anti-Nanog-Alexa Fluor 488                 1:50       Millipore, Cat\# FCABS352A4, RRID: AB_10807973
  Flow Cytometry Antibodies                                Mouse-IgM-DyLight 488                      1:50       Thermo Fischer, Cat\# MA1--194-D488, RRID: AB_2536969
  Flow Cytometry Antibodies                                Rabbit IgG-Alexa Fluor 488                 1:50       Cell Signaling, Cat\# 4340S, RRID: AB_10694568
                                                                                                                 
  -------------------------------------------------------- ------------------------------------------ ---------- --------------------------------------------------------

  --------------------------------------- --------------------------------------------------------------------------------------
  Unique stem cell line identifier        TRNDi010-C

  Alternative name(s) of stem cell line   HT592C

  Institution                             National Institutes of Health\
                                          National Center for Advancing Translational Sciences\
                                          Bethesda, Maryland, USA

  Contact information of distributor      Dr. Wei Zheng, <Wei.Zheng@nih.gov>

  Type of cell line                       iPSC

  Origin                                  Human

  Additional origin info                  Age: 16-year-old\
                                          Sex: Female\
                                          Ethnicity: Caucasian

  Cell Source                             Skin fibroblasts

  Clonality                               Clonal

  Method of reprogramming                 Integration-free Sendai viral vectors

  Genetic Modification                    Yes

  Type of Modification                    Hereditary

  Associated disease                      NGLY1 Deficiency

  Gene/locus                              NGLY1^R401X^

  Method of modification                  N/A

  Name of transgene or resistance         N/A

  Inducible/constitutive system           N/A

  Date archived/stock date                04--23--2018

  Cell line repository/bank               N/A

  Ethical approval                        NIGMS Informed Consent Form was obtained from patient at time of sample submission.\
                                          Confidentiality Certificate: CC-GM-15--004
  --------------------------------------- --------------------------------------------------------------------------------------
